It is always desirable to have more options in this space, KRAS G12c mutated NSCLC lung patients. A median duration of response above 8 months is rather exciting in this setting. Detection of such patients who may be candidates for such therapy is of critical importance.
FCS hematologist and medical oncologist James Reeves, Jr., MD co-authored a recently published study evaluating the monarchE randomized clinical trial. Findings of the study demonstrated benefits from treatment with adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, ERBB2−, node-positive, and high-risk early breast cancer who received neoadjuvant chemotherapy before trial enrollment.
This is a potential practice-changing study. Future data on overall-survival (OS) will be important to confirm results. Patient selection will also evolve over time especially in real-world practice. I presume more patients with stage II/III will get neoadjuvant therapy as opposed to a patient with a small lung nodule (stage I) taken to surgery, unless if there is significant OS for early stage patients as well.
Important clinical trial update with more mature data. Risk of death is 34% lower in combined enzalutamide and LHRH analog versus the latter alone.
Here we see a review of literature assessing the impact of patient assistance programs on outcomes broadly in cancer care. While indirect links may be drawn between the prevalence of financial toxicities and outcomes, adherence, etc., additional research studies are needed to more clearly demonstrate the tangible impact of these programs to support future investments from stakeholders.
Another study to support use of 3 months of CAPOX in lower-risk stage III colon cancer patients. Less toxicity and cost are likely observed in practice.
The risk of major adverse cardiovascular events (MACE) following the initiation of androgen deprivation therapy (ADT) in men with prostate cancer is higher for older men compared with their younger counterparts. However, the overall MACE risk at 1 year in all age groups starting ADT is 1% or less, which is much lower than previously published reports. The findings, gleaned from analyses of U.S. electronic medical records, were presented during the virtual National Comprehensive Cancer Network 2022 Annual Meeting.
Analysis of 61 NCI-designated cancers demonstrate parenteral cancer drug price markups across all centers ranging between 188.4% to 633.6%. Only 27 centers publicly disclose payer-specific prices for cancer therapies as required by federal regulation. Authors recommend public policies to discourage excessive hospital price markups on patenteral chemotherapeutics to reduce financial burden on cancer treatment for patients.
Rare disease process that can carry significant morbidity. It is encouraging to see 40% response in such patient population when no other therapies (this is a first-in class) exist besides supportive care with very favorable toxicity profile.
Interesting drug and mechanism of action in the setting of ITP. Tolerability, efficacy appeared promising. Larger studies and post-marketing RWE will be of help in analyzing this treatment option.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
